Enzymatica Balance Sheet Health
Financial Health criteria checks 6/6
Enzymatica has a total shareholder equity of SEK189.5M and total debt of SEK2.5M, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are SEK211.9M and SEK22.5M respectively.
Key information
1.3%
Debt to equity ratio
SEK 2.52m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 96.90m |
| Equity | SEK 189.49m |
| Total liabilities | SEK 22.45m |
| Total assets | SEK 211.95m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EN9's short term assets (SEK128.5M) exceed its short term liabilities (SEK21.1M).
Long Term Liabilities: EN9's short term assets (SEK128.5M) exceed its long term liabilities (SEK1.3M).
Debt to Equity History and Analysis
Debt Level: EN9 has more cash than its total debt.
Reducing Debt: EN9's debt to equity ratio has reduced from 4.1% to 1.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EN9 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EN9 has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 12% each year.